Research progress of adalimumab in pediatric Crohn 's disease / 国际儿科学杂志
International Journal of Pediatrics
;
(6): 657-660, 2019.
Article
in Chinese
| WPRIM
| ID: wpr-751533
ABSTRACT
Adalimumab is an anti-TNF-α recombinant IgG1, a fully humanized monoclonal antibody binding soluble human tumor necrosis factor alpha with high affinity and specificity. It has lower immunogenicity and can be used clinically for induction and maintenance of remission in Crohn' s disease. The effectiveness, sustainability and safety of adalimumab in the treatment of pediatric Crohn' s disease has been gradually con-firmed, which may pave the way for new therapy to treat children with refractory Crohn's disease.
Full text:
Available
Index:
WPRIM (Western Pacific)
Language:
Chinese
Journal:
International Journal of Pediatrics
Year:
2019
Type:
Article
Similar
MEDLINE
...
LILACS
LIS